TRC-00085 | Anti-Cetuximab II (Human) ELISA Kit | 96 Well
Product Overview
A competitive ELISA kit for the qualitative detection of Anti-Cetuximab II in Plasma,Serum.
Cetuximab is a recombinant human/mouse chimeric monoclonal antibody that targets the epidermal growth factor receptor (EGFR) and acts as a competitive inhibitor for both epidermal growth factor and other ligands. Binding of the antibody to EGFR causes dimerization of the receptor and endocytosis which results in cell-cycle arrest and cell death. The monoclonal antibody is used to treat several forms of cancer such as metastatic colorectal cancer, non-small cell lung cancer, head and neck cancer. anti-Cetuximab ELISA kit has been specifically developed to qualitatively determine antibodies to Cetuximab in human serum and plasma samples. The ELISA kit is based on the sandwich principle. Controls and samples (serum and plasma) are incubated in the microtiter plate coated with the drug Cetuximab. After incubation, the wells are washed and the enzymatic activity is detected by the addition of chromogen-substrate. The enzyme-substrate reaction is terminated with an acidic stop solution. The color developed is proportional to the amount of antibodies specific for Cetuximab present in the samples and controls. The qualitative test results can be evaluated using cut-off value.
Assay Information
| Assay Format | Competitive ELISA |
| Species Reactivity | Human |
| Sample Type | Plasma,Serum |
| Detection Method | Absorbance (450 nm) |
| Detection Wavelength | 450 nm |
| Kit Size | 96 Well |
Applications
This ELISA kit is used for qualitative detection of Anti-Cetuximab II in Plasma,Serum.
Features & Benefits
- Designed for qualitative detection of Anti-Cetuximab II.
- Assay format: Competitive ELISA.
- Sample type: Plasma,Serum.
- Detection method: Absorbance (450 nm).
- Kit size: 96 Well.
Storage & Shipping
| Storage | +4°C |
| Shipping | Gel Pack |
| Shelf Life | 12 Months |
Product Details
| Catalog Number | TRC-00085 |
| Analyte / Target | Anti-Cetuximab II |